Fabio D’Agostino CharaBio

Fabio is a Global Consultant and Founder of CharaBio, an innovative life science consulting firm powered by global innovation, diversity and inclusion. His ability to identify and evaluate new assets, products, services, and business models has positioned him as a trusted advisor to large organizations, VC funds and life science/biotech startups. With a keen strategic vision, he guides clients in overcoming hurdles, building value, and creating investable propositions. In 2019, he joined Claris Ventures, an €85M biotech-focused VC fund, supporting the team with equity investments in early-stage biopharma companies. In 2013, Fabio was invited to join the Parenteral Drug Association (PDA) Cell and Gene Task Force (members include executives from GSK, Novartis, Lonza, Johnson & Johnson, Adaptimmune, Takeda, Bluebird Bio) to write the Technical Report 81 about how to develop a manufacturing control strategy for cell and gene based medicinal products. Fabio initiated his career at Sorin Group (now LivaNova), a medical device company, after earning a BSc and MSc with honors in Biomedical Engineering from the Polytechnic University of Turin (Italy). Subsequently, he moved to Newcastle (UK) for an Engineering Doctorate in Biopharmaceutical Process Development at Newcastle University. He is also a Certified Lean Six Sigma Black Belt.